The NCBiotech Bio Defense program expands the life sciences base of North Carolina’s $38 billion defense economy.
Our Bio Defense outreach goes far beyond concerns over bioterrorism. NCBiotech and partners -- North Carolina’s small companies, researchers and military representatives -- are thinking more broadly. We work to provide vaccines for soldiers, to protect the food supply, and to find how best to deploy novel technologies that will protect our soldiers and heal those who sustain wounds in battle.
Information on North Carolina's Bio Defense companies in North Carolina can be found in the NCBiotech Company Directory.
For a complete list of all current COVID-19 company and research funding opportunities, please view our COVID-19 Resource webpage.
Given the size and significance of the federal investments in NC, NCBiotech and partners are working to bring the state’s innovative, life sciences technological expertise to bear to address critical challenges faced by the military and national security agencies. Developing strategies to better align the state’s well-recognized life sciences strengths with the Department of Defense (DoD) and national security strategic priorities will enable our state to be a critical solution provider on challenging problems while also increasing defense funding to support North Carolina researchers and companies.
Some of these NCBiotech-led activities include:
Providing support for university-based researchers and small businesses that have a technology that addresses a need in the Bio Defense arena and educate and support their efforts in seeking DoD or homeland security relationships and funding
Promoting and representing North Carolina at targeted military and federal Bio Defense conferences throughout the United States and promote our state's life sciences capabilities
Hosting or sponsoring conferences where military, government, academic and industry experts can network and collaborate
Connecting military, industry and academia partners to promote North Carolina’s Bio Defense capabilities at the state and federal level
For additional information, please see our Bio Defense Initiative one-pager.
Biomedical Advanced Research & Development Authority (BARDA)
For future BARDA DRIVe opportunities, sign up for the listserv.
If you or your company are developing a medical countermeasure or platform technology to combat chemical, biological, radiological, or nuclear threats, pandemic influenza or other emerging infectious diseases, you can get insights and strategic advice from HHS/ASPR Biomedical Advanced Research and Development Authority (BARDA) at a TechWatch meeting.
BARDA TechWatch meetings are your chance to introduce your proposed solution that may meet one or more of BARDA’s current priorities, and are the beginning of an important dialogue.
TechWatch meetings can be a good way in which to also get insights from other professionals from other governmental agencies with related portfolios. They can take several weeks to a couple of months to schedule so take that into consideration in your planning.
View the Latest Updates From BARDA
BARDA Division of Research, Innovation and Ventures (DRIVe)
In partnership with the National Center for Advancing Translational Sciences (NCATS), BARDA is seeking submissions for the development of advanced microphysiological systems (MPS) that can replicate components of vital human tissues and immune system functions and monitor their interactions. MPS, also called tissue chips, are 3D biophysical platforms comprised of cellular constructs that mimic the structure and function of vital human tissues and organs, such as the lungs, liver, and heart.
Under this EZ-BAA AOI, BARDA is seeking applicants with product ideas that focus on enhancing existing, fully-mature MPS that incorporate a human immune system component. These 3D platforms should include in-line sensors for continuous tissue monitoring, and utilize materials suitable for automated manufacturing and assembly of the platforms. Full proposals may be submitted until June 30, 2021.
As part of the U.S. government's ongoing public health response to the 2019 novel coronavirus (2019-nCoV), the U.S. Department of Health and Human Services (HHS) today announced the opening of an Easy Broad Agency Announcement (EZ-BAA) for development of 2019-nCoV diagnostics and is now accepting abstract submissions for potential funding. Under this EZ BAA, the Biomedical Advanced Research and Development Authority (BARDA), part of the HHS Office of the Assistant Secretary for Preparedness and Response (ASPR), will review concise abstract submissions for development funding of 2019-nCoV molecular diagnostics. The diagnostics must utilize platforms already cleared by the U.S. Food and Drug Administration, with a viable plan to meet requirements for the FDA to consider Emergency Use Authorization (EUA) within 12 weeks of an award.
"Diagnostics in close proximity to the patient are essential to ensure appropriate, prompt care and to help curb the spread of infectious diseases such as 2019-nCoV," said BARDA Director Rick Bright, PhD. "The 2019-nCoV poses a serious global health challenge, and at BARDA we are working rapidly with our government and industry partners to accelerate development of medical products needed to help protect the health of the American people."
To read the full press release, please follow this link: https://www.hhs.gov/about/news/2020/02/05/hhs-seeks-abstract-submissions-for-2019-ncov-diagnostics-development.html.
The Assistant Secretary for Preparedness and Response (ASPR) is soliciting proposals for revolutionary advancements in health security products, technologies and innovations, specifically to invigorate operations, response, recovery and medical countermeasure development, deployment and distribution activities. ASPR is seeking innovative proposals to investigate approaches that enable revolutionary advances in science, technologies, or systems. Specifically excluded are basic science, research, development, prototype and process development, data science, clinical studies, and other activities that primarily result in evolutionary improvements to the existing state of the art. ASPR is seeking approaches that are outside the mainstream, challenge assumptions, and have the potential to radically change established practice, lead to extraordinary outcomes, and create entirely new fields and commercial market disruptions with wide-ranging impact that will protect Americans from 21st Century Health Threats.
ASPR Next Areas of Interest
AOI-1: Priority Medicines on Demand
Development of transformational devices for end-to-end pharmaceutical, vaccine and/or biologics production in small-scale, modular, continuous manufacturing platforms. ASPR is also interested in developing technologies that can transform drinking water to water for sterile injection, complete with physiological additives suitable for infusion, for production at point-of-delivery.
AOI-2: Dialysis Care in Disaster Settings
Development of next-generation, portable technologies for hemodialysis in disaster settings.
AOI-3: Medical Countermeasure Deployment and Dispensing
Development of capabilities to ensure rapid deployment and dispensing of medical countermeasures or other materials to emergency response locations. This is inclusive of, but not limited to, alternate delivery methods and dispensing solutions and the development of alternative delivery platforms for pharmaceutical, vaccine and biologic administration.
AOI-4: Real-Time Healthcare System Capacity Reporting
Develop capabilities that enable secure, confidential and controlled means to track healthcare provider capacity to respond to disasters in a dynamic and timely fashion.
AOI-5: Disaster Response and Recovery Intelligence
Develop capabilities that bring together deep learning, Artificial Intelligence and Machine Learning applications to forecast disaster impacts and automate replenishment of supplies during disasters.
AOI-6: Advanced Medical Interventions
Develop capabilities to address advanced health security vulnerabilities, establish trusted data platforms to secure health-related information and investigate linkages between clinical manifestation of disease and multi-omic indicators within dedicated US-based facilities to open new pipelines for medical countermeasure discovery
AOI-7: Telehealth Applications for Response and Recovery
Establish telehealth services for medical professionals and para-professionals to better assist state, local, tribal and territorial health systems during disaster response and recovery. These teams of medical professionals and para-professionals include advanced clinicians (nurse practitioners/physician assistants), medical officers, registered nurses, respiratory therapists, paramedics, pharmacists, safety specialists, logistical specialists, information technologists, communication and administrative specialists.
AOI-8: Health Security Innovation
This Area of Interest seeks revolutionary research ideas for topics not being addressed by ongoing ASPR programs or other published solicitations.
Office of the Assistant Secretary for Preparedness & Response (ASPR)
Department of Health and Human Services
330 Independence Ave. SW
Washington, District of Columbia 20201
United States Army Medical and Materiel Command (USAMRMC)
The United States Army Medical and Materiel Command's (USAMRMC) mission is to provide solutions to medical problems of importance to the American Service member at home and abroad, as well as to the general public at large. Extramural research and development programs play a vital role in the fulfillment of the objectives established by the USAMRMC.
The FY18-FY22 USAMRMC Broad Agency Announcement (BAA) is intended to solicit extramural research and development ideas. Research and development funded through the BAA are intended and expected to benefit and inform both military and civilian medical practice and knowledge.
Read more information.